Key facts
- Status: Acquired/Merged (Operating Subsidiary).
- ·Watchlist + deal alerts for BioMeta (Shanghai)
- ·The full record, as it builds
Funding rounds
No funding rounds for BioMeta (Shanghai) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioMeta (Shanghai)
Developer of preclinical drugs designed for the biomedical industry. The company's products mainly focus on preclinical drug discovery solutions including target verification, protein production, antibody production, in vitro drug testing, cell level testing, in vivo pharmacological efficacy, pharmacokinetics, and other services, enabling the company to accelerate the development process of small molecules and biological drugs.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2022
- Employees
- 150
- Website
- biometas.cn/
- Ownership
- Acquired/Merged (Operating Subsidiary)
BioMeta (Shanghai) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioMeta (Shanghai) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioMeta (Shanghai) in its N-PORT filings yet. We sweep new filings monthly.